Infliximab antibody | AbD20436_hIgG1
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human Anti-Infliximab Antibody (clone AbD20436_hIgG1) at a concentration of 2 μg/ml followed by QuantaBlu Fluorogenic Peroxidase Substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit.
A microtiter plate was coated over night with Human IgG1/kappa, Human IgG1/lambda, cetuximab or infliximab at a concentration of 5 µg/ml. After washing with PBST and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human Anti-Infliximab Antibody (clone AbD20436_hIgG1) titrated to the given concentrations in PBST, followed by QuantaBlu Fluorogenic Peroxidase Substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit.
A microtiter plate was coated over night with Human Anti-Infliximab (clone AbD20436, HCA234) at a concentration of 0.6 µg/ml. After washing and blocking with PBST+5% BSA, 10% Human serum was added spiked with increasing concentrations of infliximab. Detection was performed using HRP-conjugated Human Anti-Infliximab (clone AbD20436_hIgG1) at a concentration of 2 µg/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit.
A microtitre plate was coated over night with infliximab at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% Human serum was added spiked with increasing concentrations of Human Anti-Infliximab (clone AbD20436_hIgG1). Detection was performed using HRP-conjugated infliximab at a concentration of 2 µg/ml in HISPEC Assay Diluent (BUF049) and QuantaBlu Fluorogenic Peroxidase Substrate. HRP-conjugation of infliximab used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit.
Filter by Application:
E ResetHuman anti Infliximab
- Product Type
- Monoclonal Antibody
- Clone
- AbD20436_hIgG1
- Isotype
- IgG1
- Specificity
- Infliximab
Quick Links:
Antibody Quality and 
Unrivaled 
| Human Anti-Infliximab Antibody, clone AbD20436_hIgG1, is an affinity matured anti-idiotypic antibody that specifically recognizes free infliximab but not infliximab bound to its target, tumor necrosis factor alpha (TNFα). It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples. This antibody inhibits the binding of infliximab to TNFα and can be used as a detection antibody in a pharmacokinetic (PK) bridging ELISA to measure free drug. As it is a fully human antibody, it can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera. Infliximab (branded as Remicade) is a chimeric IgG1 kappa monoclonal antibody approved for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. This therapeutic antibody is directed against TNFα and acts by blocking the binding of TNFα to its receptors, resulting in a down-regulation of the inflammatory response associated with autoimmune diseases. View a summary of all Anti-Infliximab Antibodies. |
- Product Form
- Pack Size: 1 mgHuman IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This product is supplied as a liquid.Pack Size: 0.1 mgHuman IgG1 antibody (kappa light chain) selected from the HuCAL? phage display library and expressed in a human cell line. This product is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Infliximab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD=0.12 nM by real time, label-free molecular interaction analysis on immobilized infliximab.
- Approx. Protein Concentrations
- Pack Size: 1 mgAntibody concentration 1.0 mg/mlPack Size: 0.1 mgAntibody concentration 0.5 mg/ml
- Regulatory
- For research purposes only
- Guarantee
- 12 months from date of despatch
- Acknowledgements
- This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Remicade is a registered trademark of Janssen Biotech Inc. Inflectra is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp.
This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |  |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in a direct ELISA or as a bridging antibody in ADA assay development.
Protocol: PK bridging ELISA to measure free drug
Protocol: ADA bridging ELISA
| Description | Product Code | Applications | Pack Size | List Price | Your Price | Quantity | |
|---|---|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Hispec Assay Diluent | ||||||
| Human anti Infliximab | HCA234 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Infliximab | ||||||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | LYNX Rapid HRP Antibody Conjugation Kit | ||||||
References for Infliximab antibody
-
Lee, M.W. et al. (2016) Comparison of infliximab drug measurement across three commercially available ELISA kits.
Pathology. Aug 23. pii: S0031-3025(16)39762-8. [Epub ahead of print]
- Synonyms
- Remicade
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
View more products with Infliximab specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up